BIO-Europe Spring® 2017: Ergomed's evolution and risk-sharing business model in practice

April 24, 2017
Over the last decade Ergomed has evolved from a contract research organization into a clinical-stage drug development company. Chief business officer Andrew Mackie tells Scrip more about this transformation and the company's relevance in 2017. Mackie, who joined the business two years ago, outlines Ergomed's risk-sharing business model and sheds light on how partnerships are made between the company and its biotech and pharma counterparts. Headquartered in London, UK, Ergomed is seeking co-development deals particularly in oncology, neurology and orphan diseases. The company currently has collaborations with Grupo Ferrer for lorediplon, an orally available non-benzodiazepine inhibitor of the gamma-aminobutyric acid A that is in development as a treatment for insomnia; Aeterna Zentaris for the development of AEZS 108 in endometrial cancer; Modus for sevuparin sodium as a treatment for patients with sickle cell disease; and others.
Previous Video
BIO-Europe Spring® 2017: vitalityDNA plans to keep healthy individuals healthy
BIO-Europe Spring® 2017: vitalityDNA plans to keep healthy individuals healthy

Precision medicines, an increased interest in the microbiome and a growing focus on wellness are some of th...

Next Video
BIO-Europe Spring® 2017: Noxxon CEO discusses partners and cancer combinations
BIO-Europe Spring® 2017: Noxxon CEO discusses partners and cancer combinations

Noxxon CEO Aram Mangasarian talks to Scrip about development plans for the company's lead compound NOX-A12,...